The Proceedings of the BIRS Community

Funder Acknowledgement

This particular project was funded by the United States Pharmacopeia Promoting the Quality of Medicines Plus (PQM+) Program, grant # 15100109.


Gentamicin is an aminoglycoside antibiotic. It is a bactericidal inhibitor of protein synthesis. It is primarily used to treat infections caused by aerobic gram-negative bacteria. Aminoglycosides are complex small molecules containing aminosugars linked to an aminocyclitol ring by glycosidic bonds.

This product information report provides expert scientific analysis of the physicochemical, biopharmaceutics, and toxicological properties, analytical, formulation, and manufacturing of gentamicin. It is expected that the PIR will provide critical information and guidance to manufacturers, as well as stakeholders concerned with access and supply of priority essential medicines.